Mental Health Clinics in Millington, MI Accepting Medicare
1 Mental Health Clinics found. Showing 1 - 1
 New Light Consultants Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 8511 State Rd, Millington, MI 48746 Phone: 989-871-6695 Fax: 989-871-3663 |
News Archive
Scientists identify proteins in mice that might act as biomarkers for growth hormone
Ohio University scientists have identified several proteins in mice that might act as biomarkers for growth hormone. The research could be the first step to finding a more reliable way to detect recombinant human growth hormone (rhGH), which some athletes and teenagers use illegally to boost muscle and reduce fat.
Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda").
U of MD researchers to use $3.7 million NIH grant to develop novel method to treat monogenic diabetes
The National Institutes of Health has awarded a four-year, $3.7 million grant to researchers at the University of Maryland School of Medicine to develop a personalized medicine program to help doctors diagnose and treat monogenic diabetes - a form of diabetes caused by a mutation in a single gene.
NHS partners with pharma giant to trial a twice-a-year jab to lower cholesterol levels
Cardiovascular disease, including heart disease and stroke, are among the top killers worldwide. Ischemic heart disease and stroke are the world's major killers, accounting for 15.2 million deaths in 2016. A high triglyceride level, combined with high low-density lipoprotein (LDL) cholesterol, is linked to atherosclerosis, which increases the risk for heart attack and stroke.
MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award
The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.
› Verified 9 days ago